June 12, 2017 / 6:38 AM / 5 months ago

BRIEF-Astrazeneca says no new safety signals from dapagliflozin trials

June 12 (Reuters) - Astrazeneca Plc:

* Data pooled from 30 phase IIB/III clinical trials for dapagliflozin showed no new safety signals

* Data pooled showed incidence of adverse events was generally similar to that in control groups​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below